利格列汀对初诊2型糖尿病患者炎症因子和动脉硬化的影响

doi:10.5246/jcps.2021.08.057

中国药学(英文版) ›› 2021, Vol. 30 ›› Issue (8): 692-698.DOI: 10.5246/jcps.2021.08.057

利格列汀对初诊2型糖尿病患者炎症因子和动脉硬化的影响

李睿¹^,^*(), 孔燕茹²

1. 山东大学第二医院急诊科, 山东济南 250033
2. 山东大学第二医院超声科, 山东济南 250033

收稿日期:2021-01-15 修回日期:2021-02-18 接受日期:2021-03-09 出版日期:2021-08-29 发布日期:2021-08-29
通讯作者: 李睿
作者简介:
+ Tel.: +86-531-85875932, E-mail: drlirui@126.com

Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus

Rui Li¹^,^*(), Yanru Kong²

1 Department of Emergency, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, Shandong, China
2 Department of Echocardiography, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, Shandong, China

Received:2021-01-15 Revised:2021-02-18 Accepted:2021-03-09 Online:2021-08-29 Published:2021-08-29
Contact: Rui Li

摘要/Abstract

摘要：

研究旨在探讨利格列汀对初诊2型糖尿病(T2DM)合并颈动脉硬化性疾病(CAD)患者的血液炎症因子水平和颈动脉内膜中层厚度(CIMT)的影响。我们将326例初诊T2DM合并CAD患者随机分为2组, 对照组163例二甲双胍单药治疗, 实验组163例在二甲双胍基础上联合利格列汀治疗。彩色超声多普勒测量治疗前后CIMT, ELISA法检测治疗前后IL-6和IL-1β数值, 比较两组治疗前后炎症因子水平和CIMT厚度, 并分析IL-6和IL-1β与CIMT的相关性。治疗24周后, 结果显示实验组的炎症因子水平和CIMT均显著低于对照组(P < 0.01), IL-6和IL-1β的水平与CIMT呈正相关。通过本研究得出利格列汀对初诊T2DM合并CAD患者的血液炎症因子水平和CIMT均有改善作用, IL-6、IL-1β可能通过影响CIMT参与CAD的发生和发展。

关键词: 利格列汀, 2型糖尿病, 颈动脉硬化性疾病, 炎症因子, 颈动脉内膜中层厚度

Abstract:

In the present study, we aimed to investigate the effects of linagliptin on inflammatory factors and carotid intima-media thickness (CIMT) in newly diagnosed type 2 diabetes mellitus (T2DM) patients with carotid atherosclerotic disease (CAD). A total of 326 patients with newly diagnosed T2DM complicated with CAD were randomly divided into two groups. There were 163 patients in the control group, who were treated with metformin monotherapy. There were 163 patients in the experimental group, who were treated with metformin in combination with linagliptin. The CIMT before and after treatment was measured by color Doppler ultrasound, and the contents of IL-6 and IL-1β before and after treatment were detected by ELISA. The levels of inflammatory factors and CIMT before and after treatment were compared between the two groups, and the correlation between IL-6, IL-1β and CIMT was studied. After 24 weeks of treatment, the levels of inflammatory factors and CIMT in the experimental group were significantly lower compared with the control group (P < 0.01), and the serum levels of IL-6 and IL-1β were positively correlated with CIMT. In the present study, we concluded that linagliptin could improve the levels of inflammatory factors and CIMT in newly diagnosed T2DM patients with CAD, and IL-6 and IL-1β might participate in the occurrence and development of CAD by influencing CIMT.

Key words: Linagliptin, Type 2 diabetes mellitus, Carotid atherosclerosis disease, Inflammatory factors, Carotid intima-media thickness

Supporting:

李睿, 孔燕茹. 利格列汀对初诊2型糖尿病患者炎症因子和动脉硬化的影响[J]. 中国药学(英文版), 2021, 30(8): 692-698.

Rui Li, Yanru Kong. Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 692-698.

图/表 5

Table 1. Comparison of general data between the experimental group and control group.

Table 2. Comparison of IL-6, IL-1β, CIMT, and HbA1c between the experimental group and control group. (*Compared with before treatment, P < 0.01).

Figure 1. CIMT before (left) and after treatment (right).

Figure 2. Correlation between IL-6 and CIMT.

Figure 3. Correlation between IL-1β and CIMT.

参考文献 18

[1]	Gupta, R.; Walunj, S.S.; Tokala, R.K.; Parsa, K.V.L.; Singh, S.K.; Pal, M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr. Drug Targets. 2009, 10, 71–87.
[2]	Hwang, H.J.; Jung, T.W.; Ryu, J.Y.; Hong, H.C.; Choi, H.Y.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Choi, K.M.; Choi, D.S.; Baik, S.H.; Yoo, H.J. Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes. Mol. Cell Endocrinol. 2014, 392, 1–7.
[3]	Li, R.; Song, L.H.; Liu, J.; Bai, Y.; Du, Y.M.; Lin, C.H.; Su, X.Y.; Yu, Z.X. Cardioprotective effect of Linagliptin on diabetic Wistar rats. J. Chin. Pharm. Sci. 2021, 30, 334–346.
[4]	Araki, E.; Unno, Y.; Tanaka, Y.; Sakamoto, W.; Miyamoto, Y. Long-term efficacy and safety of linagliptin in a Japanese population with type 2 diabetes Aged ≥ 60 years treated with basal insulin: a randomised trial. Adv. Ther. 2019, 36, 2697–2711.
[5]	Senchenkova, E.Y.; Russell, J.; Yildirim, A.; Granger, D.N.; Gavins, F.N.E. Novel role of T cells and IL-6 (interleukin-6) in angiotensin II-induced microvascular dysfunction. Hypertens. Dallas Tex. 2019, 73, 829–838.
[6]	Khan, R.; Rheaume, E.; Tardif, J.C. Examining the role of and treatment directed at IL-1β in atherosclerosis. Curr. Atheroscler. Rep. 2018, 20, 53.
[7]	Grzanka, M.; Matejko, B.; Szopa, M.; Kiec-Wilk, B.; Malecki, M.T.; Klupa, T. Assessment of newly proposed clinical criteria to Identify HNF1AMODY in patients with an initial diagnosis of type 1 or type 2 diabetes mellitus. Adv. Med. 2016, 2016, 1–3.
[8]	Zhu, Y.H.; Xian, X.M.; Wang, Z.Z.; Bi, Y.C.; Chen, Q.G.; Han, X.F.; Tang, D.Q.; Chen, R.J. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 2018, 8, 80.
[9]	Li, J.J.; Zhao, X.Q.; Meng, X.; Lin, J.X.; Liu, L.P.; Wang, C.X.; Wang, A.X.; Wang, Y.L.; Wang, Y.J.;. High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome. Stroke. 2016, 47, 2025–2030.
[10]	Song, Y.X.; Dou, H.; Li, X.J.; Zhao, X.Y.; Li, Y.; Liu, D.; Ji, J.J.; Liu, F.; Ding, L.; Ni, Y.H.; Hou, Y.Y. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1β-primed mesenchymal stem cells against sepsis. STEM CELLS. 2017, 35, 1208–1221.
[11]	Qu, H.P.; Liu, Z.J.; Liu, J.L. Measurement of monocyte apoptosis, plasma IL-1β and PR3 activity as an approach to evaluate the immunological status in sepsis. Crit. Care. 2011, 15, 434.
[12]	Böni-Schnetzler, M.; Donath, M.Y. Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance? Cell Res. 2011, 21, 995–997.
[13]	Finucane, O.M.; Lyons, C.L.; Murphy, A.M.; Reynolds, C.M.; Klinger, R.; Healy, N.P.; Cooke, A.A.; Coll, R.C.; McAllan, L.; Nilaweera, K.N.; O’Reilly, M.E.; Tierney, A.C.; Morine, M.J.; Alcala-Diaz, J.F.; Lopez-Miranda, J.; O’Connor, D.P.; O’Neill, L.A.; McGillicuddy, F.C.; Roche, H.M. Monounsaturated fatty acid–enriched high-fat diets impede adipose NLRP3 inflammasome–mediated IL-1β secretion and insulin resistance despite obesity. Diabetes. 2015, 64, 2116–2128.
[14]	Tong, L.L.; Adler, S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad. Med. 2018, 130, 381–393.
[15]	Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; Holst, J.J.; Langhans, W.; Meier, J.J.; Nauck, M.A.; Perez-Tilve, D.; Pocai, A.; Reimann, F.; Sandoval, D.A.; Schwartz, T.W.; Seeley, R.J.; Stemmer, K.; Tang-Christensen, M.; Woods, S.C.; DiMarchi, R.D.; Tschöp, M.H. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130.
[16]	Ta, N.N.; Schuyler, C.A.; Li, Y.; Lopes-Virella, M.F.; Huang, Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 2011, 58, 157–166.
[17]	Nezu, T.; Hosomi, N.; Aoki, S.; Matsumoto, M. Carotid intima-media thickness for atherosclerosis. J. Atheroscler. Thromb. 2016, 23, 18–31.
[18]	Centurión, O.A. Carotid intima-media thickness as a cardiovascular risk factor and imaging pathway of atherosclerosis. Crit. Pathw. Cardiol. 2016, 15, 152–160.

利格列汀对初诊2型糖尿病患者炎症因子和动脉硬化的影响

Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 18

相关文章 11

编辑推荐

Metrics

本文评价

[1]	卢磊, 邱成英, 陈谦. 莲花清瘟颗粒联合头孢噻肟钠对小儿肺炎患儿疗效及血清炎症因子的影响[J]. 中国药学(英文版), 2023, 32(11): 947-953.
[2]	黄嘉欢, 岳玲, 张铭儒, 杨全, 程轩轩. 辣蓼对大肠杆菌性腹泻小鼠炎症因子和细胞色素P450酶表达的影响[J]. 中国药学(英文版), 2022, 31(8): 622-633.
[3]	李荣, 宋利华, 刘杰, 白杨, 杜玉茗, 林春华, 苏秀媛, 于宗学. 利格列汀对糖尿病Wistar大鼠心脏保护作用的研究[J]. 中国药学(英文版), 2021, 30(4): 334-346.
[4]	姚烨, 酒向飞, 王思媛, 卢炜, 周田彦. 西他列汀影响糖尿病大鼠中二肽基肽酶活性、胰岛素和血糖水平的基于机制的药物动力学/药效动力学模型研究[J]. 中国药学(英文版), 2018, 27(6): 371-382.
[5]	张烨, 郑丹萍, 水梦洋, 刘晔, 刘晓岩, 王银叶. 新化合物W026B通过抑制炎性细胞因子的产生减轻缺血性脑损伤, 与tPA合用作用增强[J]. 中国药学(英文版), 2018, 27(10): 675-685.
[6]	管晓东, 马莉莉, 王国英, 海沙尔江·吾守尔, 满春霞, 韩晟, 史录文. 中国2型糖尿病患者胰岛素注射笔用针头重复使用的影响因素研究[J]. 中国药学(英文版), 2018, 27(1): 51-58.
[7]	杨倩, 陈刚, 杨洋, 蔡雪婷, 庞中化, 胡春萍, 张双全, 曹鹏. 刺芒柄花素通过诱导Nrf2表达缓解DSS诱导的小鼠溃疡性结肠炎[J]. 中国药学(英文版), 2016, 25(3): 178-188.
[8]	胡琴, 唐惠林, 邵宏. 基于肠促胰素药物治疗2型糖尿病合并非酒精性肝病的疗效和安全性的系统评价和meta分析[J]. 中国药学(英文版), 2016, 25(3): 206-214.
[9]	姚莉, 范芳芳, 胡兰, 赵生俊, 郑丽丽. 沙格列汀治疗成人2型糖尿病的有效性和安全性: 基于随机对照试验的meta分析[J]. 中国药学(英文版), 2016, 25(2): 128-139.
[10]	谢晓慧, 王菲, 崔家玉. 糖尿病管理中的肥胖问题及其干预[J]. 中国药学(英文版), 2015, 24(6): 412-418.
[11]	林珠灿, 张龙, 张睿卓, 黄安玉, 郭素华. 基于炎症细胞模型的景天三七醋酸乙酯部位抗炎活性及其HPLC指纹图谱的研究[J]. 中国药学(英文版), 2015, 24(10): 647-653.